论文部分内容阅读
目的筛选发热伴血小板减少综合征布尼亚病毒(severe fever with thrombocytopenia syndrome bunyavirus,SFTSV)疫苗候选株,为后续疫苗的研制奠定了基础。方法取长成致密单层的Vero细胞,接种疫苗候选株,待细胞充分病变时,收获病毒培养液上清,经病毒滴度、抗体效价、抗原含量、交叉保护性及传代稳定性共5个评价指标筛选SFTSV疫苗生产用毒株,建立3级毒种库,并进行鉴定。结果经首轮筛选获得3株次轮候选株,经次轮筛选确定JS-2011-013株为疫苗生产用毒株,建立的3级种子库经全面检定,均符合《中国药典》三部(2010版)要求。结论已成功获得到SFTSV疫苗生产用毒株,为后续疫苗的研制奠定了基础。
Objective To screen candidate strains of fever with thrombocytopenia syndrome bunyavirus (SFTSV) vaccine, and lay a foundation for further vaccine development. Methods Vero cells growing into dense monolayer were inoculated with vaccine candidate strains. When the cells were fully diseased, the supernatant of the virus culture medium was harvested. The virus titer, antibody titer, antigen content, cross protection and passage stability were all 5 A selection of screening indicators SFTSV vaccine production strains, the establishment of Class 3 virus library, and identification. Results Three rounds of candidate strains were screened by the first round of screening. JS-2011-013 strain was selected as the strain for vaccine production by the second round of screening. The established seed bank of grade 3 was fully tested and all were in conformity with the three parts of Chinese Pharmacopoeia 2010 version) requirements. Conclusion SFTSV vaccines have been successfully obtained and laid the foundation for the development of subsequent vaccines.